



ONLINE

MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021

25th May 2021, Tuesday 16:00 BST | 08:00 PDT



MEDICINAL CHEMISTRY



BIOLOGY

FACILITATOR FACULTY

SPONSORS

AGENDA

KEYNOTE PRESENTATION

TRACK 1: Artificial Intelligence / Machine Learning

TRACK 2: Chemical Biology & Cheminformatics

TRACK 3: Design & Custom Synthesis

TRACK 4: Hit To Lead Identification

TRACK 5: Integrated Drug Discovery

TRACK 6: In Vivo & In Vitro Pharmacology

TRACK 7: Target Discovery, Identification & Validation

TRACK 8: DMPK, ADME & Toxicology

TRACK 9: Strategic Partnerships, Collaborations & Alliance Management

Click here to find out what our clients think about our STRATEGY MEETINGS



OUR VISION

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

OUR MISSION

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

OUR UNIQUE ONLINE MEETING FORMAT



Roundtable Discussions

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.



Personalised Agenda

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.



Innovative Solutions

Whatever your challenge may be, let our official event partners find the solution. Gain access to our carefully selected solution providers and find your next strategic partner that will help take your business to the next level.



Strategic Networking

Strategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

LEADING INSIGHTS FROM

Uli Schmitz

Executive Director,
Structural Chemistry
Gilead Sciences



Yvonne Will

Vice President, Predictive
and Investigative Toxicology
(Nonclinical Safety),
Janssen R&D, J&J



Mike Petrassi

VP, Medicinal Chemistry
Calibr/Scripps
Research



Prasun Mishra

CEO
Agility
Pharmaceuticals



Danilo Maddalo

Head of Laboratory
Roche



Tudor Oprea

Professor of Medicine and
Chief, Translational
Informatics Division,
Department of Internal
Medicine, University of
New Mexico



Bill Shirley

Senior Director,
Structural
Chemistry
Gilead Sciences



Yuhua Ji

Head of Medicinal
Chemistry
Zai Lab US



PROVENTA
INTERNATIONAL

GET IN TOUCH WITH US:



UK: +44 (0)207 096 1222
US: +44 (0)20 3314 0100



info@proventainternational.com



www.proventainternational.com

Connect with us



FACILITATOR FACULTY

ONLINE

MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY



Paul Galatsis
VP, Chemistry
Vibriome Therapeutics



Robert Hilgraf
Senior Director, Medicinal
Chemistry, **REVOLUTION**
Medicines



Yuhua Ji
Head of Medicinal Chemistry
Zai Lab US



Ellen Kats, Ph.D
Assistant Director, Licensing
University of California San
Francisco



**Jacqueline
Kinyamu-Akunda**
Sr. Scientific Dir., Nonclinical
Safety, Janssen R&D



Peter Kotsonis
Exec. Dir., Office of Strategic
Alliances, **University of**
California San Francisco



Danilo Maddalo
Head of Laboratory
Roche



Katherine Matsumoto
Director, Product
Management
Recursion Pharmaceuticals



Prasun Mishra
Founder, CEO
Agility
Pharmaceuticals



Tudor Oprea
Prof. of Medicine and Chief,
Translational Informatics Division,
Department of Internal Medicine
University of New Mexico



Mike Petrassi
VP, Medicinal Chemistry
Calibr/Scripps Research



Werner Rubas
Executive Director
Nektar Therapeutics



Mathias Schmidt
CEO
ArmaGen Inc.



Uli Schmitz
Executive Director,
Structural Chemistry
Gilead Sciences



Bill Shirley
Senior Director,
Structural Chemistry
Gilead Sciences



Nick Shah
Head of In Vitro
Pharmacology
DiCE Molecules



Hiroomi Tada
Chief Medical Officer
Tyra Biosciences



Cathy Tralau-Stewart
Senior Director
Alliances Takeda



Vuong Trieu
Chairman & CEO
Mateon Therapeutics



Dr. Bonnie Wang
Manager
Bristol-Myers Squibb



Yvonne Will
VP, Predictive and Investigative
Toxicology (Nonclinical Safety),
Janssen R&D, J&J



David Wustrow
Vice President at Discovery
RAPT Therapeutics



OUR SPONSORS



MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY

LEAD SPONSOR



[Visit Website](#)

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated.”

CO-HOST SPONSORS



[Visit Website](#)

Nanome is changing how we understand, design, and interact with science. Nanome's immersive virtual workspaces allow users to visualize, modify, and simulate chemical compounds, proteins, and nucleic acids to help improve the Drug Discovery process. Our virtual reality platform facilitates effective communication of structural data in drug discovery which has proved beneficial to several pharmaceutical and biotech companies across the globe. This is especially helpful for organizations that are interested in improving their cross-site collaboration. Learn more about Nanome at <https://nanome.ai/>



[Visit Website](#)



[Visit Website](#)

BirdoTech is a chemistry services CRO headquartered in Shanghai China. With clients across North America, Europe, and Asia, BirdoTech delivers quality products with utmost stringent criteria while meeting demanding timelines. Our laboratories are equipped with the latest in advanced instrumentations to provide reliable data that are critical for decision-making. To meet our clients' demand, we employ >100 scientists and expanded our R&D labs in Shanghai and Xi'an to 4,000 m2. Further expansion with pilot plants are in Baiyin, Gansu and Jinan, Shandong.

KEY OPINION LEADER



[Visit Website](#)



PART 1 AGENDA









MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY

TRACK & TIME		1	ARTIFICIAL INTELLIGENCE / MACHINE LEARNING	2	CHEMICAL BIOLOGY & CHEMINFORMATICS	3	DESIGN & CUSTOM SYNTHESIS	4	HIT TO LEAD IDENTIFICATION	5	INTEGRATED DRUG DISCOVERY
(BST)	(PDT)										
16:00-16:30	08:00-08:30	KEYNOTE OPENING SESSION									
16:30-16:45	08:30-08:45	BREAK									
16:45-17:45	08:45-09:45	Evaluating the impact of AI generative methods and ML models in drug discovery Uli Schmitz — <i>Executive Director, Structural Chemistry, Gilead Sciences</i>	Translating Novel Academic Research into Driving Professional Pharma Standards in Drug Discovery Programs Mike Petrassi — <i>VP, Medicinal Chemistry, Calibr/Scripps Research</i>	Optimizing autonomy in synthesis: discussing the current state and outlook towards better efficiency	Novel strategies to balancing high-throughput capabilities with multi-parametric studies	Effective Integration of Multidisciplinary Teams to Ensure Seamless Drug Discovery Processes Yuhua Ji — <i>Head of Medicinal Chemistry, Zai Lab US</i>					
17:45-18:00	09:45-10:00	BREAK									
18:00-18:30	10:00-10:30	NEW! — END USER PANEL SESSION The Great Debate: The Utilization of True AI in All Aspects of Drug Discovery									
18:30-18:45	10:30-10:45	BREAK									
18:45-19:45	10:45-11:45	Harnessing the technology of noisy intermediate-scale quantum (NISQ) in drug discovery 	Discussing strategies in modeling of chemical reactions at larger scales	Furthering the new paradigm: the marriage of robotics and advanced analytics in drug design Topic TBC for Sponsor	In Silico Design and Molecular Glues Carla Gauss — <i>Senior Application Scientist, Medicinal Chemistry, Nanome</i> 	Advancing cycle time, analysis and purification efficiency through novel technologies and innovative approaches 					
19:45-20:00	11:45-12:00	BREAK									
20:00-20:30	12:00-12:30	 KEYNOTE SESSION		 KEYNOTE SESSION							
20:30-20:45	12:30-12:45	BREAK									
20:45-21:45	12:45-13:45	Beyond the AI hype: What has worked, and what will be improved in the future? Bill Shirley — <i>Senior Director, Structural Chemistry, Gilead Sciences</i>	Leveraging DNA-encoded libraries and cheminformatics to discover novel reactions and chemistries	How does the target integrate with the clinical side? What can we do to ensure success in the clinic? Paul Galatsis — <i>VP, Chemistry, Vibliome Therapeutics</i>	Computational Methods for Hit to Lead Optimization - how do we prioritize good from bad? David Wustrow — <i>Vice President, Discovery, RAPT Therapeutics</i>	Partnering and Licensing with an Academic Medical Center Peter Kotsonis & Ellen Kats, Ph.D (Co-host) — <i>Executive Director, Office of Strategic Alliances, UCSF & Assistant Director, Licensing, UCSF</i>					
21:45-22:00	13:45-14:00	BREAK									
22:00-23:00	14:00-15:00	Beyond the Hype of New Machine Learning Technology and Onto Delivery Tudor Oprea — Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine, University of New Mexico	Evaluating the challenges surrounding obtaining and structuring the right data sets Katherine Matsumoto — <i>Director, Product Management, Recursion Pharmaceuticals</i>	Novel computational approaches to design next gen drugs keeping optimized scale up and yield in mind	Targeting Protein-Protein Interactions (PPIs) – Challenges and Technologies Robert Hilgraf — <i>Senior Director, Medicinal Chemistry, REVOLUTION Medicines</i>	Reinstating phenotypic screening in your drug discovery workflow: discover novel phenotypes brought by innovative screening tools Prasun Mishra — <i>CEO, Agility Pharmaceuticals</i>					
23:00	15:00	END OF DAY									



PART 2 AGENDA








MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY

TRACK & TIME (BST) (PDT)		6	IN VIVO & IN VITRO PHARMACOLOGY	7	TARGET DISCOVERY, IDENTIFICATION & VALIDATION	8	DMPK, ADME & TOXICOLOGY	9	STRATEGIC PARTNERSHIPS, COLLABORATIONS & ALLIANCE MANAGEMENT
16:00-16:30	08:00-08:30	KEYNOTE OPENING SESSION							
16:30-16:45	08:30-08:45	BREAK							
16:45-17:45	08:45-09:45		Future Challenges and Solutions with Advanced In-Vitro Assay Systems – A Look at Phenotypic and Biomarker Assays Danilo Maddalo — <i>Head of Laboratory, Roche</i>		The Need for Better Targets for Solid Tumor Targeting with High Potency Modalities		Assay Development for the Near Future – How to Solve Problems In Early Stage Predictive Assays For PK and Toxicology Yvonne Will & Jacqueline Kinyamu-Akunda (Co-host) — <i>Vice President, Predictive and Investigative Toxicology (Nonclinical Safety), Janssen R&D & Senior Scientific Director, Nonclinical Safety, Janssen R&D</i>		Strategic Biopharma Partnerships – Marriage for Love Versus Being a Means to an End Mathias Schmidt — <i>CEO, ArmaGen Inc.</i>
17:45-18:00	09:45-10:00	BREAK							
18:00-18:30	10:00-10:30	NEW! — END USER PANEL SESSION The Great Debate: The Utilization of True AI in All Aspects of Drug Discovery							
18:30-18:45	10:30-10:45	BREAK							
18:45-19:45	10:45-11:45		In Vitro “Mode of Action” and In Vivo Outcome Measures and Toxicological Studies - What Can Be Farmed Out to Specialist Companies? 		Overcoming the Limitations of Target Validation Tools. Can Future Tools Shift the Field Towards Innovation? 		Implementing AI for Decision Making in Drug Discovery: How Can Applying AI in DMPK Impact Drug Discovery? Topic TBC for Sponsor		Implementing Open Innovation in the Industry: Joining Pharmaceuticals, Biotechs and Academia Together to Accelerate R&D Processes Topic TBC for Sponsor
19:45-20:00	11:45-12:00	BREAK							
20:00-20:30	12:00-12:30				KEYNOTE SESSION				KEYNOTE SESSION 
20:30-20:45	12:30-12:45	BREAK							
20:45-21:45	12:45-13:45		New Tools and Technologies - Can 3D Culture, HiPSC and Organ-on-chip Technologies Help to Bridge the Translational Medicine Gap? Nick Shah — <i>Head of In Vitro Pharmacology, DiCE Molecules</i>		TGF-beta Target for COVID-19 Therapies Vuong Trieu — <i>Chairman & CEO, Mateon Therapeutics</i>		Translation of Pre-Clinical PK of PEGylated Biologics to Man Werner Rubas & Dr. Bonnie Wang (Co-Host) — <i>Executive Director, Nektar Therapeutics & Manager, Bristol-Myers Squibb</i>		Maximizing Value Through Biology-Driven Strategic Outsourcing and Partnership
21:45-22:00	13:45-14:00	BREAK							
22:00-23:00	14:00-15:00		Can In-Silico Modeling Bridge the Gap Between Non-Clinical and Clinical Data? A Critical Look at the Advantages and Limitations for Practical Application		How Do We Improve Our Hit Rate for Target Validation Cathy Tralau-Stewart — <i>Senior Director Alliances, Takeda</i>		Solutions to Mitigate Against ADME Related Issues Early in the Drug Discovery Project – A Critical Discussion		Innovative Clinical Trials - How can non-profits and patient advocates help address unmet patient needs in oncology clinical trials Hiroomi Tada — <i>Chief Medical Officer, Tyra Biosciences</i>
23:00	15:00	END OF DAY							



KEYNOTE PRESENTATION




MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY




Speaker
TBC

KEYNOTE OPENING SESSION

🕒 16:00 - 16:30 BST

🕒 08:00 - 08:30 PDT

Topic TBC




Speaker
TBC

INDUSTRY PANEL SESSION

🕒 18:00 - 18:30 BST

🕒 10:00 - 10:30 PDT

The Great Debate: The
Utilization of True AI in All
Aspects of Drug Discovery



WuXi AppTec

KEYNOTE SESSION

🕒 20:00 - 20:30 GMT

🕒 12:00 - 12:30 PDT

Topic TBC



TRACK 1

Artificial Intelligence / Machine Learning



ONLINE

MEDICINAL CHEMISTRY & BIOLOGY

STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY



Uli Schmitz


Executive Director, Structural Chemistry
Gilead Sciences

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

Evaluating the impact of AI generative methods and ML models in drug discovery

- How do we evaluate AI generative design methods ?
- How to best implement AI generative design methods, technically and culturally?
- Are ML models having an impact in lead optimization?



WuXi AppTec

SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT



Harnessing the technology of noisy intermediate-scale quantum (NISQ) in drug discovery - Title TBC



Bill Shirley

Senior Director, Structural Chemistry
Gilead Sciences

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

Beyond the AI hype: What has worked, and what will be improved in the future?



Tudor Oprea

Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine
University of New Mexico

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

Beyond the Hype of New Machine Learning Technology and Onto Delivery

- How do we build and use ML models?
- Are we moving closer to delivering on our end goal?
- The industrial process by which we incorporate ML into daily drug discovery activities.



TRACK 2

Chemical Biology & Cheminformatics



ONLINE

MEDICINAL CHEMISTRY & BIOLOGY

STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY




Mike Petrassi
VP, Medicinal Chemistry
Calibr/Scripps Research

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

Translating Novel Academic Research into Driving Professional Pharma Standards in Drug Discovery Programs

- How to Improve Assays to Medicinal Chemistry Standards.
- How to Do the Appropriate Hit Finding - Experimentally and Computationally
- What Are the Right Experimental Chemistry and Drug Discovery Questions to Ask?




Speaker
TBC

SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT

Discussing strategies in modeling of chemical reactions at larger scales



Speaker
TBC

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

Leveraging DNA-encoded libraries and cheminformatics to discover novel reactions and chemistries



Katherine Matsumoto
Director, Product Management
Recursion Pharmaceuticals

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

Evaluating the challenges surrounding obtaining and structuring the right data sets

- The need for data sets to meet the question we're trying to answer.
- Turning research problems into software problems – how to turn data research projects into production code.
- Bringing together technical experts and SME talents to answer questions in new ways and maintain collaborative and innovative work environments.



TRACK 3

Design & Custom Synthesis



ONLINE


MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY




Speaker
TBC

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

Optimizing autonomy in synthesis: discussing the current state and outlook towards better efficiency



Speaker
TBC

SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT

Furthering the new paradigm: the marriage of robotics and advanced analytics in drug design




Paul Galatsis
VP, Chemistry
Vibliome Therapeutics

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

How does the target integrate with the clinical side? What can we do to ensure success in the clinic?

- How novel are our approaches to tackling the same targets?
- Evaluating the methods and approaches that have gone in and out of fashion.
- Understanding how we organise our organisational structure to work faster and more efficiently – lessons learnt from working in-house, hybridising or outsourcing.



Speaker
TBC

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

Novel computational approaches to design next gen drugs keeping optimized scale up and yield in mind



TRACK 4

Hit to Lead Identification



ONLINE

MEDICINAL CHEMISTRY & BIOLOGY


STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY



Speaker
TBC

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

Novel strategies to balancing high-throughput capabilities with multi-parametric studies



Carla Gauss
Senior Application Scientist,
Medicinal Chemistry
Nanome

SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT



In Silico Design and Molecular Glues

- First designed molecular glue identified in 1996 (FK-1012)
- Discovery of molecular glue degraders and their mechanism of action
- First molecular glue in clinical trials and in silico design of WDB002



David Wustrow
Vice President,
Discovery
RAPT
Therapeutics

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

Computational Methods for Hit to Lead Optimization - how do we prioritize good from bad?



Robert Hilgraf
Senior Director,
Medicinal Chemistry
REVOLUTION Medicines

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

Targeting Protein-Protein Interactions (PPIs) – Challenges and Technologies

- Established technologies to target PPIs
- Novel technology approaches - A case study presentation
- Pros and cons for the different technologies



TRACK 5

Integrated Drug Discovery



MEDICINAL CHEMISTRY & BIOLOGY

STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY



Yuhua Ji


Head of Medicinal Chemistry
Zai Lab US

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

Effective Integration of Multidisciplinary Teams to Ensure Seamless Drug Discovery Processes

- How we create value by working side-by-side as chemists with biologists and data scientists.
- Ensuring support at the start of each project and full understanding of the targets and tools to use.
- Working with other teams to understand data generated from other groups.



BioDuro

SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT



Advancing cycle time, analysis and purification efficiency through novel technologies and innovative approaches - Title TBC



Peter Kotsonis

Executive Director, Office of Strategic Alliances, UCSF

(CO-HOST)



Ellen Kats, Ph.D

Assistant Director, Licensing UCSF

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

Partnering and Licensing with an Academic Medical Center

- Leveraging academic medical centers for innovation – from drug targets, to therapeutics to drug discovery platforms
- Navigating a modern technology transfer office – understanding the structure, the relationship with faculty and, campus incentives & policies
- Finding the right model for a pharma or biotech – a collaboration or asset in-licensing
- Different business partnering models – programmatic examples at UC San Francisco
- Asset licensing - the mechanics of a licensing deal



Prasun Mishra

CEO

**Agility
Pharmaceuticals**

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

Reinstating phenotypic screening in your drug discovery workflow: discover novel phenotypes brought by innovative screening tools



TRACK 6

In Vivo & In Vitro Pharmacology

ONLINE

MEDICINAL CHEMISTRY & BIOLOGY

STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY




Danilo Maddalo
Head of Laboratory
Roche

16:45 - 17:45 BST

08:45 - 09:45 PDT

Future Challenges and Solutions with Advanced In-Vitro Assay Systems – A Look at Phenotypic and Biomarker Assays



WuXi AppTec

SPONSOR

18:45 - 19:45 BST

10:45 - 11:45 PDT



In Vitro “Mode of Action” and In Vivo Outcome Measures and Toxicological Studies - What Can Be Farmed Out to Specialist Companies? - Title TBC




Nick Shah
Head of In Vitro Pharmacology
DiCE Molecules

20:45 - 21:45 BST

12:45 - 13:45 PDT

New Tools and Technologies - Can 3D Culture, HiPSC and Organ-on-chip Technologies Help to Bridge the Translational Medicine Gap?



Speaker
TBC

22:00 - 23:00 BST

14:00 - 15:00 PDT

Can In-Silico Modeling Bridge the Gap Between Non-Clinical and Clinical Data? A Critical Look at the Advantages and Limitations for Practical Application



TRACK 7

Target Discovery, Identification & Validation




MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY




Speaker
TBC

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

The Need for Better Targets for Solid Tumor Targeting with High Potency Modalities

- Have peptide HLA targets reached their tipping point?
- The modality of targeting peptide HLA – Does this matter?
- How do we deal with HLA diversity?



WuXi AppTec


SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT



Overcoming the Limitations of Target Validation Tools. Can Future Tools Shift the Field Towards Innovation? - Title TBC



Vuong Trieu
Chairman & CEO
Mateon Therapeutics

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

TGF-beta Target for COVID-19 Therapies

- Do we believe TGF-beta plays a role in covid-19?
- What are the mechanisms to control and knockdown TGF-beta?
- The clinical consequences



Cathy Tralau-Stewart
Senior Director
Alliances
Takeda

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

How Do We Improve Our Hit Rate for Target Validation

- Tackling the Issue of Attrition Rate in Early Drug Discovery.
 - Getting Validation Right - the key to improving how many projects that need to be performed to ensure success in the clinic.
 - How to Collaborate with Experts in Academia.



TRACK 8

DMPK, ADMET & Toxicology



ONLINE

MEDICINAL CHEMISTRY & BIOLOGY

STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY




BIOLOGY



Yvonne Will

Vice President, Predictive and Investigative
Toxicology (Nonclinical Safety)
Janssen R&D

(CO-HOST)




Jacqueline Kinyamu-Akunda
Senior Scientific Director, Nonclinical Safety
Janssen R&D

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

Assay Development for the Near Future – How to Solve Problems In Early Stage Predictive Assays For PK and Toxicology




Speaker
TBC

SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT

Implementing AI for Decision Making in Drug Discovery: How Can Applying AI in DMPK Impact Drug Discovery?



Werner Rubas
Executive Director
Nektar Therapeutics

(CO-HOST)




Dr. Bonnie Wang
Manager
Bristol-Myers Squibb

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

Translation of Pre-Clinical PK of PEGylated Biologics to Man

- How does the Pre-Clinical Development plan look like for PEGylated proteins?
- What studies are needed and which ones are nice to have?



Speaker
TBC

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

Solutions to Mitigate Against ADME Related Issues Early in the Drug Discovery Project – A Critical Discussion



TRACK 9

Strategic Partnerships,
Collaborations & Alliance
Management



MEDICINAL CHEMISTRY & BIOLOGY STRATEGY MEETING WEST COAST USA 2021



MEDICINALCHEMISTRY



BIOLOGY




**Mathias
Schmidt**
CEO
ArmaGen Inc.

🕒 16:45 - 17:45 BST

🕒 08:45 - 09:45 PDT

Strategic Biopharma Partnerships – Marriage for Love Versus Being a Means to an End

- Finding the right partnership that truly appreciates the value all parties bring to the table
- Making them sustainable – tools and secrets for alignment, success and dispute resolution
- How to maintain independence and avoid hand-cuffing agreement clauses




**Speaker
TBC**

SPONSOR

🕒 18:45 - 19:45 BST

🕒 10:45 - 11:45 PDT

Implementing Open Innovation in the Industry: Joining Pharmaceuticals, Biotechs and Academia Together to Accelerate R&D Processes




**Speaker
TBC**

🕒 20:45 - 21:45 BST

🕒 12:45 - 13:45 PDT

Maximizing Value Through Biology-Driven Strategic Outsourcing and Partnership



Hiroomi Tada
Chief Medical Officer
Tyra Biosciences

🕒 22:00 - 23:00 BST

🕒 14:00 - 15:00 PDT

Innovative Clinical Trials - How can non-profits and patient advocates help address unmet patient needs in oncology clinical trials

- How are clinical trials not meeting the needs of patient populations?
- How can non-profits and patient advocacy groups be involved to help meet the needs of patients in clinical trials?
- Novel ways in which the industry and non-profit organizations can work together to conduct innovative oncology trials.

